Skip to main content
Top
Published in: BMC Endocrine Disorders 1/2021

Open Access 01-12-2021 | Obesity | Research article

Associations between obesity, weight change and decreased renal function in Korean type 2 diabetic patients: a longitudinal follow-up study

Authors: Bo-Yeon Kim, Dug-Hyun Choi, Chan-Hee Jung, Ji-Oh Mok, Chul-Hee Kim

Published in: BMC Endocrine Disorders | Issue 1/2021

Login to get access

Abstract

Background

We aimed to examine the associations between the risk of decreased renal function, obesity, and weight changes in Korean type 2 diabetic patients with normal renal function.

Methods

Type 2 diabetic patients (n = 1060) who visited the diabetic clinic at Soonchunhyang University Bucheon Hospital between 2001 and 2007 with follow up surveys completed in 2016 to 2017 were recruited into the study. Decreased renal function was defined as an estimated glomerular filtration rate < 60 mL/min/1.73 m2. Weight change was calculated between baseline and each follow-up survey. Multivariate analysis was used to evaluate the longitudinal association of baseline obesity and weight changes with the risk of decreased renal function.

Results

This study revealed that baseline obesity was associated with the risk of decreased renal function after adjusting for clinical variables in type 2 diabetic patients (odds ratio [OR] 1.40; 95% confidence intervals [CI] 1.08–2.04; p = 0.025). Follow-up (mean = 12 years) revealed that weight gain > 10% was associated with the risk of decreased renal function after adjusting for clinical variables in type 2 diabetic patients with normal renal function at baseline (OR 1.43; CI 1.11–2.00; p = 0.016). Weight loss was not associated with the risk of decreased renal function in type 2 diabetic patients with normal renal function at baseline.

Conclusions

Baseline obesity was associated with the increased risk of decreased renal function in Korean type 2 diabetic patients with normal renal function. Weight gain > 10% independently predicted the risk of decreased renal function. Large prospective studies are needed to clarify causal associations between obesity, weight change, and decreased renal function in patients with type 2 diabetes.
Literature
6.
go back to reference Tsuboi N, Utsunomiya Y, Hosoya T. Obesity-related glomerulopathy and the nephron complement. Nephrol Dial Transplant. 2013;28(Suppl 4):iv108–13.CrossRef Tsuboi N, Utsunomiya Y, Hosoya T. Obesity-related glomerulopathy and the nephron complement. Nephrol Dial Transplant. 2013;28(Suppl 4):iv108–13.CrossRef
7.
go back to reference Mallamaci F, Tripepi G. Obesity and CKD progression: hard facts on fat CKD patients. Nephrol Dial Transplant. 2013;28(Suppl 4):iv105–8.CrossRef Mallamaci F, Tripepi G. Obesity and CKD progression: hard facts on fat CKD patients. Nephrol Dial Transplant. 2013;28(Suppl 4):iv105–8.CrossRef
12.
go back to reference Organization, W.H, The Asia-Pacific perspective: redefining obesity and its treatment. 2000. Organization, W.H, The Asia-Pacific perspective: redefining obesity and its treatment. 2000.
34.
go back to reference Tang J, Yan H, Zhuang S. Inflammation and oxidative stress in obesity-related glomerulopathy. Int J Nephrol. 2012;2012:608397.CrossRef Tang J, Yan H, Zhuang S. Inflammation and oxidative stress in obesity-related glomerulopathy. Int J Nephrol. 2012;2012:608397.CrossRef
Metadata
Title
Associations between obesity, weight change and decreased renal function in Korean type 2 diabetic patients: a longitudinal follow-up study
Authors
Bo-Yeon Kim
Dug-Hyun Choi
Chan-Hee Jung
Ji-Oh Mok
Chul-Hee Kim
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2021
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-021-00853-z

Other articles of this Issue 1/2021

BMC Endocrine Disorders 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.